← Startup Fundraising

AI megachecks meet Founders Fund’s $6B growth haul (May 02, 2026)

May 02, 2026 · 4m 53s · Listen

AI megachecks, Founders Fund’s 6 billion dollar growth haul, and a fundraising tape that is very much awake.

This is Startup Fundraising — the rounds and VC moves shaping Saturday’s tech market, from brain-inspired AI and AGI labs to data tooling, space-made cancer therapies, and one massive growth fund.

Big checks, big ambitions. Yeah — let’s get into it.

Absolutely. First up: the AI efficiency bet pulling in about half a billion dollars.

From The Next Web:

Thomas Reardon, who created Internet Explorer and sold neural interface startup CTRL-labs to Meta for up to $1 billion, is raising approximately $500 million for Flourish at a $2.5 billion valuation. The startup uses connectomics and neuroscience to design AI architectures that are radically more energy-efficient, targeting the architectural layer above silicon rather than building new chips. Lux Capital and GV, who backed CTRL-labs, are expected to lead the round.

That Flourish pitch is pretty fascinating. They’re not showing up with another chip story — they’re going after the way AI architectures are designed. If compute is the squeeze point, then architecture starts looking like the place everyone wants to dig.

Next, from Amit Chowdhry:

Standard Intelligence, a San Francisco-based AI research company focused on building aligned artificial general intelligence, has raised $75 million in new funding from Sequoia and Spark Capital. The investors joining the round include Sonya Huang and Mikowai Ashwill from Sequoia and Yasmin Razavi from Spark Capital, all of whom the company describes as deeply supportive of its long-term mission.

Seventy-five million dollars for a six-person AGI lab — that pretty much sums up the AI funding cycle right now. Tiny team, enormous mission, and investors trying to get close to the next frontier-model story. The real test is whether “aligned AGI” turns into an actual roadmap, or just a very expensive research banner.

Also on the AI stack, from Menlotimes:

Encord, the data layer behind the world's leading AI, led by Eric Landau and Ulrik Stig Hansen, has raised$60 million in Series C funding led by Wellington Management to scale its AI-native data infrastructure as physical AI hits an inflection point. The round also included participation from existing investors Y Combinator, CRV, N47, and Crane Venture Partners, and new investors Bright Pixel and Isomer Capital, bringing the total funding to $110 Million.

This is the infrastructure side of the AI boom — the data layer, the cleanup, the governance, all the plumbing that makes models work outside a demo. And if robotics, drones, and autonomous systems are picking up, then investors are clearly betting the leverage sits in clean, continuously refined data.

Now, from ET:

Peter Thiel’s Founders Fund has secured a record $6 billion for its latest growth-stage fund, primarily from external limited partners. This rapid deployment of capital reflects a trend of mature startups seeking substantial private investment over public offerings. The fund will focus on a dozen concentrated bets, continuing the firm's strategy of backing marquee companies.

Six billion dollars is a very loud signal. Founders Fund is betting that the best late-stage companies can keep raising privately, away from the IPO window. Fewer bets, bigger checks, and the public markets are not being treated like the obvious next stop.

And one more from Amit Chowdhry:

BioOrbit, a biotech company developing in-space manufacturing of cancer therapies, has closed a £9.8 million ($13.2 million) seed round, which the company describes as the largest seed round in the history of in-space manufacturing. The round was co-led by LocalGlobe and BREEGA, with support from Seedcamp, Auxxo Female Catalyst Fund, Type One Ventures, 7percent Ventures, and others.

This is the space story that actually matters: manufacturing cancer therapies in orbit. The dream is huge — the hard part is whether “made in orbit” can ever become cheap and reliable enough to beat Earth-based biotech at scale.

We’ve linked the sources for every story in today’s show notes, so if one of these caught your attention, you can head there and read a little deeper.

That’s Startup Fundraising for today. This is a Lantern Podcast.